BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liao KF, Lai HC, Lin CL, Lai SW. Letter: cohort study examining the association between proton pump inhibitor therapy and risk of hepatocellular carcinoma in Taiwan. Aliment Pharmacol Ther 2018;48:689-90. [PMID: 30132939 DOI: 10.1111/apt.14905] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Lai SW. Letter to the Editor: Proton Pump Inhibitor Use and Risk of Hepatocellular Carcinoma. Hepatology 2019;70:440. [PMID: 30289991 DOI: 10.1002/hep.30302] [Reference Citation Analysis]
2 Singh A, Hussain S, Jha R, Jayraj AS, Klugar M, Antony B. Proton pump inhibitor use and the risk of hepatocellular carcinoma: A systematic review of pharmacoepidemiological data. J Evid Based Med 2021. [PMID: 34643998 DOI: 10.1111/jebm.12456] [Reference Citation Analysis]
3 Shao YJ, Wu SY. Letter: cohort study examining the association between proton pump inhibitors therapy and risk of hepatocellular carcinoma in Taiwan-authors' reply. Aliment Pharmacol Ther 2018;48:690-1. [PMID: 30132942 DOI: 10.1111/apt.14935] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]